Method of treating inflammation by administering antibody molecules which bind IL-17A and IL-17F
AssigneeUcb Biopharma Sprl
InventorsRalph Adams, Andrew George Popplewell, Stephen Edward Rapecki
Life of this patent
Estimating the term…
Abstract
The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Claims9
A method of treating inflammation associated with an increased level of IL-17A and/or IL-17F in a subject in need thereof comprising administering to the subject an antibody which binds human IL-17A and human IL-17F, wherein the variable domain of the antibody heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3, and wherein the variable domain of the antibody light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3, or an antigen binding fragment thereof.
A method of treating inflammation associated with an increased level of IL-17A and/or IL-17F in a subject in need thereof comprising administering to the subject an antibody which binds human IL-17A and human IL-17F, wherein the antibody binds to the same epitope on human IL-17A and/or human IL-17F and/or IL-17A/F heterodimer as a neutralising antibody which binds human IL-17A and human IL-17F, and comprises a heavy chain variable region having the amino acid sequence given in SEQ ID NO:9 and a light chain variable region having the amino acid sequence given in SEQ ID NO:7.
Dependencies are inferred from the claim text.